Guardant Health said the FDA has approved Guardant360 Liquid CDx, expanding its blood-based comprehensive genomic testing platform and making it the largest FDA-approved liquid biopsy panel. The approval adds regulatory validation to the company’s oncology diagnostics offering and supports broader adoption of its genomic/epigenomic testing technology. The update is positive for Guardant Health, though the article provides no revenue, usage, or financial magnitude.
Guardant Health said the FDA has approved Guardant360 Liquid CDx, expanding its blood-based comprehensive genomic testing platform and making it the largest FDA-approved liquid biopsy panel. The approval adds regulatory validation to the company’s oncology diagnostics offering and supports broader adoption of its genomic/epigenomic testing technology. The update is positive for Guardant Health, though the article provides no revenue, usage, or financial magnitude.
AI-powered research, real-time alerts, and portfolio analytics for institutional investors.
Request DemoOverall Sentiment
moderately positive
Sentiment Score
0.65
Ticker Sentiment
